This startup develops a skin biomarker platform for precision medicine in chronic autoimmune diseases. Their non-invasive technology painlessly retrieves biomarkers from the skin's surface, providing a clinical decision support system that helps physicians prescribe personalized biologic therapies more effectively.
Funding
Funding not disclosed
Founders
Product
Problem
Prescribing biologic drugs for chronic autoimmune diseases often involves a trial-and-error approach, leading to delayed effective treatment, unnecessary side effects, and increased healthcare costs. A significant percentage of patients are either non-responders or achieve only partial response, necessitating multiple treatment switches.
Solution
DermaBio offers a precision medicine platform that utilizes skin biomarker analysis to predict a patient's response to biologic therapies. The platform employs a non-invasive skin swab to collect biomarkers, which are then analyzed using proprietary AI-powered algorithms and advanced data modeling techniques. This analysis generates a clinician report with actionable insights, enabling physicians to select the most appropriate biologic therapy for each patient, reducing the need for trial and error. By predicting treatment response, DermaBio aims to improve patient outcomes, optimize drug utilization, and reduce overall healthcare expenditures associated with autoimmune disease management.
Target Audience
The primary target audience includes clinicians specializing in autoimmune diseases, payers seeking to optimize drug utilization and reduce costs, and pharmaceutical companies looking for real-world patient insights to enhance clinical trial design.
Features
- Non-invasive 30-second skin sample collection at the point of care
- Proprietary clinical assay for skin biomarker analysis
- AI-powered algorithms to analyze skin biomarkers and clinical data
- Advanced data modeling to generate predictive insights
- Predictive biomarker platform applicable to autoimmune, neurodegenerative, and oncology conditions
- Clinical reports to match patients with optimal biologic therapies
- Capability to predict response to non-biologic therapies